Innoviva, Inc. (INVA) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Royalty Revenue from Glaxo Group Limited | 58.6M | FY2026-Q1 |
| Net Product Sales | 41.4M | FY2026-Q1 |
| Giapreza Net Product Sales | 19.7M | FY2026-Q1 |
| Net Product Sales Excluding the United States | 7.2M | FY2026-Q1 |
| Net Product Sales in the United States | 34.2M | FY2026-Q1 |
| Xerava Net Product Sales | 2.5M | FY2026-Q1 |
| Xacduro Net Product Sales | 11.6M | FY2026-Q1 |
| Giapreza Net Product Sales in the United States | 18.2M | FY2025-Q3 |
| Xacduro Net Product Sales in the United States | 8.5M | FY2025-Q3 |
| Xerava Net Product Sales in the United States | 3.2M | FY2025-Q3 |
| Zevtera Net Product Sales in the United States | 100K | FY2025-Q3 |
Back to INVA overview · INVA earnings · INVA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.